IFN-γ and TNF-α induce a different modulation of interleukin-6 in systemic sclerosis fibroblasts compared to healthy controls

Scand J Rheumatol. 2011 Nov;40(6):453-6. doi: 10.3109/03009742.2011.585349. Epub 2011 Jul 4.

Abstract

Background: To our knowledge, no previous study has evaluated the effect of interferon (IFN)-γ, tumour necrosis factor (TNF)-α, or their combination on the prototype proinflammatory cytokine interleukin (IL)-6 in primary cultured fibroblasts from patients with systemic sclerosis (SSc) at an early stage of the disease.

Methods: Fibroblast cultures from five SSc patients (disease duration < 2 years) and five healthy controls were evaluated for the basal production of IL-6, and after stimulation with TNF-α or IFN-γ, alone or combined.

Results: The fibroblasts from SSc patients produced higher levels of IL-6 in basal condition than controls [617 ± 173 vs. 213 ± 123 pg/mL; analysis of variance (ANOVA), p < 0.001]. TNF-α was able to dose-dependently induce IL-6 in SSc (609 ± 184, 723 ± 243, 1079 ± 297, 1436 ± 326 pg/mL, with TNF-α 0, 1, 5, 10 ng/mL, respectively) but not in control fibroblasts, whereas IFN-γ was unable to induce IL-6. Furthermore, the combination of IFN-γ and TNF-α induced a stronger secretion of IL-6 in SSc fibroblasts (ANOVA, p < 0.0001), without effect in controls.

Conclusions: SSc fibroblasts participate in the self-perpetuation of inflammation by releasing IL-6, under the influence of TNF-α and/or IFN-γ.

MeSH terms

  • Adult
  • Aged
  • Case-Control Studies
  • Cells, Cultured
  • Drug Therapy, Combination
  • Female
  • Fibroblasts / drug effects*
  • Fibroblasts / metabolism
  • Humans
  • Inflammation / immunology
  • Interferon-gamma / pharmacology*
  • Interleukin-6 / metabolism*
  • Male
  • Middle Aged
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / metabolism
  • Tumor Necrosis Factor-alpha / pharmacology*

Substances

  • Interleukin-6
  • Tumor Necrosis Factor-alpha
  • Interferon-gamma